A T-cell therapy that targets a protein only expressed on HPV-positive cancers has shown low toxicity and impressive responses in some patients enrolled in a phase 1/2 clinical trial.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Researchers showed that survival in pancreatic cancer may be influenced by the tumor microbiome and that tumor growth can be influenced via fecal transplantation.
Immune checkpoint inhibitor therapies have improved survival in patients with non-small cell lung cancer, but they have also been linked to immune-related adverse events affecting various organs, including the lungs.
